ABBV Jan 2025 210.000 put
- Reuters
AbbVie raises annual profit forecast on strong Skyrizi sales
AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. The company now expects adjusted profit of between $11.13 and $11.33 per share for this year, compared with $10.97 to $11.17 estimated earlier. Analysts on average expect annual profit of $11.10 per share, according to LSEG data.
- PR Newswire
AbbVie Reports First-Quarter 2024 Financial Results
AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2024.
- Reuters
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
